Oral matrix formulations comprising licarbazepine

Details for Australian Patent Application No. 2005226910 (hide)

Owner Novartis AG

Inventors Kalb, Oskar; Wolf, Marie-Christine

Agent Davies Collison Cave

Pub. Number AU-B-2005226910

PCT Pub. Number WO2005/092294

Priority 0406379.8 22.03.04 GB; 0406738.5 25.03.04 GB

Filing date 21 March 2005

Wipo publication date 6 October 2005

Acceptance publication date 4 June 2009

International Classifications

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

Event Publications

21 September 2006 PCT application entered the National Phase

  PCT publication WO2005/092294 Priority application(s): WO2005/092294

4 June 2009 Application Accepted

  Published as AU-B-2005226910

8 October 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005226911-Use of rotigotine for treating and preventing Parkinson's plus syndrome

2005226909-Disintegrating tablets comprising licarbazepine